Reviva Pharmaceuticals Holdings Inc Ordinary Shares RVPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RVPH is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
-
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
-
REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
-
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
-
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
-
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
Trading Information
- Previous Close Price
- $2.94
- Day Range
- $2.80–3.05
- 52-Week Range
- $2.67–9.22
- Bid/Ask
- $2.80 / $2.81
- Market Cap
- $78.17 Mil
- Volume/Avg
- 181,316 / 256,276
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease, and Parkinson’s disease psychosis and its other drug candidate is RP1208.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- https://www.revivapharma.com
Comparables
Valuation
|
Metric
|
RVPH
|
ITCI
|
RYTM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 13.71 | 11.60 | 15.36 |
Price/Sales | — | 14.77 | 32.68 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RVPH
|
ITCI
|
RYTM
|
|---|---|---|---|
Quick Ratio | 1.36 | 4.95 | 5.27 |
Current Ratio | 1.38 | 5.41 | 5.58 |
Interest Coverage | — | — | −13.26 |
Quick Ratio
RVPH
ITCI
RYTM
Profitability
|
Metric
|
RVPH
|
ITCI
|
RYTM
|
|---|---|---|---|
Return on Assets (Normalized) | −249.99% | −13.47% | −46.12% |
Return on Equity (Normalized) | −1,399.08% | −15.88% | −76.97% |
Return on Invested Capital (Normalized) | −1,302.76% | −17.96% | −76.40% |
Return on Assets
RVPH
ITCI
RYTM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jrzwjgbkt | Tzdn | $567.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rlhglpvk | Rssdvn | $106.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tjvxpfbyg | Rgbcql | $104.0 Bil | |
MRNA
| Moderna Inc | Wdtdychtd | Rfhh | $46.4 Bil | |
ARGX
| argenx SE ADR | Zvvqqlst | Lggp | $23.2 Bil | |
BNTX
| BioNTech SE ADR | Vwzchnlg | Ztv | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yxnvrxxt | Bnhhqp | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dxgdncnz | Nyjwl | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lqdpgjwdxh | Yztdn | $12.7 Bil | |
INCY
| Incyte Corp | Ghntmtfy | Ymphcdx | $12.2 Bil |